Shopping Cart
- Remove All
- Your shopping cart is currently empty
Gartisertib (VX-803) is an orally active and selective Rad3-related protein (ATR) inhibitor with antitumor activity, inhibiting the antiproliferative effect induced in ccRCC cells, and inhibiting ATR-driven phosphorylation of checkpoint kinase 1 (Chk1), useful for studying solid tumors.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $136 | In Stock | |
5 mg | $338 | In Stock | |
10 mg | $565 | In Stock | |
25 mg | $1,130 | In Stock | |
50 mg | $1,570 | In Stock | |
100 mg | $2,360 | In Stock | |
1 mL x 10 mM (in DMSO) | $403 | In Stock |
Description | Gartisertib (VX-803) is an orally active and selective Rad3-related protein (ATR) inhibitor with antitumor activity, inhibiting the antiproliferative effect induced in ccRCC cells, and inhibiting ATR-driven phosphorylation of checkpoint kinase 1 (Chk1), useful for studying solid tumors. |
Targets&IC50 | ATR:8 nM |
In vitro | Gartisertib was four times more potent in all glioblastoma cell lines than the widely used ATR inhibitor berzosertib (Gartisertib median IC50 = 0.56 μM, berzosertib median IC50 = 2.21 μM). In addition, Gartisertib observed a higher IC50 (7.22 μM) in human astrocytes, indicating a lower potential toxicity of Gartisertib to normal brain cells. The combination of Gartisertib (1 μM) with TMZ+RT significantly increased apoptosis and cell death in patient-derived glioblastoma cell lines. [1] |
In vivo | Gartisertib (10 mg/kg or 20 mg/kg) plus cisplatin inhibited tumor growth in metastatic clear cell renal cell carcinoma (ccRCC) xenografts, demonstrating therapeutic synergies. [2] |
Alias | VX-803, VX 03, VRT1228692, M4344, M 4344, ATR inhibitor 2 |
Molecular Weight | 541.55 |
Formula | C25H29F2N9O3 |
Cas No. | 1613191-99-3 |
Smiles | O=C(NC=1C=NC=C(F)C1N2CCC(C(=O)N3CCN(CC3)C4COC4)CC2)C=5C(=NN6C=C(F)C=NC56)N |
Relative Density. | 1.31g/cm3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||
Solubility Information | DMSO: 16 mg/mL (29.54 mM), Sonication is recommended. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.